-
公开(公告)号：US10246469B2
公开(公告)日：2019-04-02
申请号：US15763281
申请日：2016-09-29
发明人： Joanne J. Bronson , Ling Chen , Jonathan L. Ditta , Carolyn Diane Dzierba , Prasada Rao Jalagam , Guanglin Luo , John E. Macor , Tarun Kumar Maishal , Susheel Jethanand Nara , Ramkumar Rajamani , Ramesh Kumar Sistla , Soodamani Thangavel
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D237/08 , C07D239/26 , C07D213/34 , A61K31/50 , A61K31/51 , A61K31/505 , A61K31/506 , A61K31/44 , A61K31/4427 , A61P25/28 , C07D513/04 , A61P25/18 , A61P25/16 , C07D213/74
摘要： The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
-
2.发明申请METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40 审中-公开使用针对CD40指导的抗体的TRANSPLANT抑制剂治疗方法公开(公告)号：US20170051059A1
公开(公告)日：2017-02-23
申请号：US15122455
申请日：2015-03-19
IPC分类号： C07K16/28 , A61K39/395 , A61K38/17 , C07K14/705
CPC分类号： C07K16/2818 , A61K38/00 , A61K38/1774 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K14/70521 , C07K14/70575 , C07K16/2875 , C07K2317/21 , C07K2317/40 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , A61K2300/00
摘要： Methods of treating renal transplant rejection using anti-CD40L domain antibodies are provided. The anti-CD40L dAbs are less likely to cause platelet aggregation and thus cause thromboembolism. Appropriate anti-CD40L dAbs doses and administration regimens are also provided. Combination treatments for transplant rejection, particularly renal transplant rejection, using anti-CD40L dAbs, a CTLA4 mutant molecule (e.g., belatacept) and/or anti-CD28 optionally with conventional immunosuppressive renal transplant therapy are provided.
摘要翻译： 提供了使用抗CD40L结构域抗体治疗肾移植排斥的方法。 抗CD40L dAb不太可能引起血小板聚集，从而引起血栓栓塞。 还提供了适当的抗CD40L dAb剂量和给药方案。 提供了使用抗CD40L dAb，CTLA4突变分子（例如belatacept）和/或任选用常规免疫抑制性肾移植治疗的抗CD28的移植排斥特别是肾移植排斥的组合治疗。
-
公开(公告)号：US09765018B2
公开(公告)日：2017-09-19
申请号：US14897668
申请日：2014-07-01
发明人： Jay A. Markwalder , Steven P. Seitz , James Aaron Balog , Audris Huang , Sunil Kumar Mandal , David K. Williams , Amy C. Hart , Jennifer Inghrim
IPC分类号： C07C275/42 , C07C311/51 , C07D213/75 , C07D257/04 , C07D401/04 , A61K31/18 , A61K31/41 , A61K31/44 , C07D213/79 , C07D307/86 , A61K31/196 , A61K31/277 , A61K31/343 , A61K31/4418 , A61K31/444 , A61K45/06 , C07C311/09 , C07D307/79
CPC分类号： C07C275/42 , A61K31/18 , A61K31/196 , A61K31/277 , A61K31/343 , A61K31/41 , A61K31/4418 , A61K31/444 , A61K45/06 , C07C311/09 , C07C311/51 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D213/75 , C07D213/79 , C07D257/04 , C07D307/79 , C07D307/86 , C07D401/04
摘要： There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20200339662A1
公开(公告)日：2020-10-29
申请号：US16813094
申请日：2020-03-09
发明人： Jonathan DAVIS , Dasa LIPOVSEK , Ray CAMPHAUSEN
摘要： Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US10253027B2
公开(公告)日：2019-04-09
申请号：US14902868
申请日：2014-07-01
发明人： Richard A. Hartz , Vijay T. Ahuja , Joanne J. Bronson , Carolyn Diane Dzierba , John E. Macor , Susheel Jethanand Nara , Ramkumar Rajamani
IPC分类号： C07D487/04 , C07D409/10 , C07D233/61 , C07D401/12 , C07D401/10 , C07D263/32 , C07D213/56 , C07D285/12 , C07D277/30 , C07D213/73 , C07D213/65 , C07D249/08 , C07D233/54 , C07D249/06 , C07D237/08 , C07D213/72 , C07D213/16 , C07D285/08 , C07D231/12 , C07D213/62 , C07D277/20 , C07D213/61 , C07D263/30 , C07D413/12 , C07D417/12
摘要： The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
-
6.发明申请公开(公告)号：US20170137514A1
公开(公告)日：2017-05-18
申请号：US15296290
申请日：2016-10-18
发明人： Nils LONBERG , Mohan SRINIVASAN
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2818 , C07K16/2827 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US20040171876A1
公开(公告)日：2004-09-02
申请号：US10788728
申请日：2004-02-26
发明人： Jingyang Zhu , Scott T. Chadwick , Benjamin A. Price , Shannon X. Zhao , Carrie A. Costello , Purushotham Vemishetti
IPC分类号： C07C229/02
CPC分类号： C07C255/29 , C07C227/10 , C07C227/16 , C07C227/18 , C07C227/22 , C07C227/40 , C07C227/42 , C07C253/30 , C07C255/28 , C07C229/26
摘要： Provided are processes and synthetic intermediates useful for the preparation of null-difluoromethylornithine (DFMO) having the formula 1
-
公开(公告)号：US09790169B2
公开(公告)日：2017-10-17
申请号：US15088211
申请日：2016-04-01
发明人： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC分类号： C07C229/42 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C255/58 , C07C275/40 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D309/14 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56
CPC分类号： C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
摘要： There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20240360235A1
公开(公告)日：2024-10-31
申请号：US18628224
申请日：2024-04-05
发明人： Vladimir CORIC , Tibor KELER , Thomas DAVIS
CPC分类号： C07K16/2878 , A61K39/00 , A61K39/0008 , A61K39/0011 , A61K39/001129 , A61K39/00115 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/2818 , C07K16/3023 , C07K16/3046 , C07K16/3053 , C07K16/3069 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/73 , C07K2317/75 , C07K2317/76
摘要： This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
-
公开(公告)号：US12129264B2
公开(公告)日：2024-10-29
申请号：US17415237
申请日：2019-12-20
IPC分类号： C07D513/04 , A61K31/433 , A61K45/06 , A61P7/02 , C07C55/10 , C07C59/265
CPC分类号： C07D513/04 , A61K31/433 , A61K45/06 , A61P7/02 , C07C55/10 , C07C59/265 , C07B2200/13
摘要： The present invention relates to co-crystals of the compound of formula (I), wherein the co-former molecule is succinic acid or citric acid, processes for the preparation of the co-crystal, pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
搜索结果
4587 条记录 (耗时 0.039 秒)
